Genenta Science - GNTA Enterprise Value-to-Sales Ratio

Public company logo of Genenta Science S.p.A. (GNTA)

Genenta Science S.p.A. (GNTA) is investing in R&D for cellular cancer therapies, which is temporarily increasing expenses. This complements an expansion strategy into the solid tumor segment via Temferon vectors. The company's current price-to-sales valuation reflects market dynamics, where the parameter has stabilized at 0.00. Business development relies on attracting leading geneticists through competitive salaries and extensive social benefits.

Genenta Science SpA (GNTA): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/04/2026

Financial and market metric breakdowns for Genenta Science (GNTA)

Fundamental valuation:Genenta Science SpA (GNTA)
Core merchandise of genenta.com

The investment attractiveness of Genenta Science S.p.A. (GNTA) is based on the inelastic demand for its unique oncology therapy, which allows the market to price in a high premium to the business value. Current EV/Sales dynamics reflect the ratio of enterprise value to revenue excluding leverage, demonstrating how much an investor is willing to pay per unit of sales while ignoring the impact of debt load on capitalization.